Lilly reflects on how 'Mirror' projects share costs, derisk early development
This article was originally published in Scrip
After quietly working behind the scenes for the past couple of years to help create three venture capital funds intended to back early-stage research, Lilly revealed 15 February that the first of those funds has acquired two molecules and is ready to get down to business, although many details of the drug maker's so-called Mirror Portfolio project remain under wraps.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.